MMSI

Merit MedicalA

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$105.00

Analysis reference price unavailable

Analysis 2026-09-12 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$94.00

Analysis reference price unavailable

Analysis 2026-09-12 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$72.00

Analysis reference price unavailable

Analysis 2026-09-12 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-12

AI commentary

Primary-source tone is constructive following an expectation-beating Q2 and raised 2026 guidance, but recent news coverage is sparse and no sufficient social, options, short-interest, employee, or post-print analyst-revision data was supplied. The numerical sentiment fields without packet coverage are unavailable proxies rather than observed signals and should not influence the thesis. The $86.36 anchor is below the COO's August 24 sale price, but no causal inference should be drawn from that comparison.

RankAlpha Sentiment Codex - 2026-09-12

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventExecution against raised full-year 2026 guidanceHigh impact

Merit raised 2026 revenue guidance to $1.631-$1.643 billion and non-GAAP EPS guidance to $4.25-$4.35 after Q2 results exceeded its expectations. Delivery through year-end would support estimate confidence; the catalyst is partly reflected in the shares. [#SEC-8K-2026-07-30]

2026-12-31catalystTherapeutic portfolio growth durabilityHigh impact

Q2 therapeutic revenue grew 14% in constant currency, led by Cardiac Therapies and Endoscopy growth of 22% and 29%, respectively. Confirmation that these gains persist while Foundational Procedural Solutions and Renal Therapies stabilize would improve the quality of the growth outlook. [#SEC-8K-2026-07-30]

2027-06-30catalystOperating leadership and longer-term strategic-plan executionMedium impact

Sheri Lewis became Executive Vice President of Global Operations effective August 31, while management is developing a longer-term plan aimed at sustainable growth and enhanced profitability. Evidence of operational improvements or credible post-2026 targets could broaden the thesis, but neither outcome is quantified yet. [#8-K-2026-08-20] [#SEC-8K-2026-07-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-12 • Updated nightlySource: Internal modelMethodology